Truist Securities Reiterates Buy Rating on PGNY
Truist Securities maintains its Buy rating on PGNY, setting a target price of $33, a 26.53% upside from the current price.
Key Points
- Truist Securities reiterated its Buy rating on PGNY with a new price target of $33 on June 22, 2026.
- Truist Securities's $33 price target implies 26.53% upside from Progyny, Inc.'s ($PGNY) current $26.08 share price.
- PGNY shares traded at $26.08 on Monday, reflecting market confidence in the company's growth potential.
- Recent insider transactions include planned sales by key executives, while institutional investors like BlackRock reduced their holdings.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Truist Securities reiterated its Buy rating on PGNY, setting a target price of $33. This update comes as the company continues to attract attention from investors and analysts alike. PGNY shares traded at $26.08 on Monday, indicating a positive outlook from the market.
Truist Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in PGNY
Several institutional investors have made notable changes to their PGNY holdings. BlackRock, Inc. reduced its position by 960,152 shares, leaving it with about 11.99 million shares valued at approximately $203.7 million, a 7.4% decrease. FMR LLC also trimmed its stake by 66,091 shares, ending with 6.5 million shares worth about $110.4 million, a 1.0% decrease. On the other hand, Vanguard Portfolio Management LLC and Vanguard Capital Management LLC both opened new positions in PGNY, acquiring 5,292,028 and 3,481,339 shares, respectively. State Street Corp increased its holdings by 127,107 shares to reach a total of 3,080,293 shares, a 4.3% rise, while Ameriprise Financial Inc boosted its stake by 547,282 shares to 2,825,331 shares, marking a 24.0% increase.
Progyny, Inc. Stock Up 0.3%
PGNY shares were trading near $26.08 on Monday. The stock has seen varied interest from institutional investors and analysts, reflecting its dynamic position in the market.
$PGNY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Progyny, Inc.
Recent insider activity at PGNY includes planned sales by key executives. On June 4, 2026, Mark Livingston, the Chief Financial Officer, sold 2,517 shares at an average price of $25.50 under a Rule 10b5-1 plan. Additionally, Allison Swartz, Executive Vice President and General Counsel, sold 599 shares at $25.08, also under a planned sale. There were additional unplanned sales by both Livingston and Swartz on the same date.
Analysts Set New Price Targets
On June 22, 2026, Truist Securities maintained its Buy rating on PGNY with a $33 price target. Earlier in the month, B of A Securities also maintained a Buy rating with a $31 target on June 2, 2026. Canaccord Genuity upgraded PGNY to a Buy with a $30 target on May 19, 2026. Barclays maintained its Buy rating with a $27 target on May 18, 2026, reflecting a consistent positive sentiment among analysts.
Bottom Line
Truist Securities' reiteration of its Buy rating and the new $33 price target for PGNY highlights ongoing confidence in the company's market potential. Institutional activity shows a mix of reductions and new entries, indicating diverse strategies among investors. Insider sales, particularly planned ones, are a regular part of executive financial management. As always, 13F filings and analyst ratings provide a backward-looking view and should be considered as part of a broader investment strategy.
Get Progyny, Inc. alerts
New 13F filings, insider trades, and analyst moves on $PGNY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.